3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Mach7 Technologies's 3-Year ROIIC % for the quarter that ended in Jun. 2025 was 68.98%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Mach7 Technologies's 3-Year ROIIC % or its related term are showing as below:
ASX:M7T's 3-Year ROIIC % is ranked better than 86.8% of 621
companies
in the Healthcare Providers & Services industry
Industry Median: 3.46
vs ASX:M7T: 68.98
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Mach7 Technologies 3-Year ROIIC % Related Terms
Mach7 Technologies 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Mach7 Technologies's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:M7T vs VEEV, BTSG, TEM: 3-Year ROIIC % Comparison
For the Health Information Services subindustry, Mach7 Technologies's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mach7 Technologies 3-Year ROIIC % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Mach7 Technologies's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Mach7 Technologies's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Mach7 Technologies (ASX:M7T) has a 3-Year ROIIC % of 68.98 as of Jun. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Mach7 Technologies and its competitors. According to the industry distribution chart, Mach7 Technologies ranks #82 out of 621 companies in the Healthcare Providers & Services industry, placing it in the top 13.2%.
Is Mach7 Technologies' 3-Year ROIIC % too high?
Mach7 Technologies' current 3-Year ROIIC % is 68.98. The Healthcare Providers & Services industry median 3-Year ROIIC % is 3.46. Mach7 Technologies' value of 68.98 is 1893.6% above this industry median. Based on the distribution chart, Mach7 Technologies ranks #82 out of 621 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Mach7 Technologies has a GF Score™ of 29/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Mach7 Technologies' 3-Year ROIIC % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Mach7 Technologies ranks #82 out of 621 companies for 3-Year ROIIC %. This places Mach7 Technologies in the top 13% of its industry — outperforming the majority of peers. The industry median 3-Year ROIIC % is 3.46. Mach7 Technologies' value of 68.98 is 1893.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Healthcare Providers & Services company?
The median 3-Year ROIIC % among Healthcare Providers & Services companies is 3.46, based on 621 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mach7 Technologies's current 3-Year ROIIC % of 68.98 is 1893.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Mach7 Technologies and its competitors. For the Healthcare Providers & Services industry, the median 3-Year ROIIC % is 3.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mach7 Technologies's current 3-Year ROIIC % is 68.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mach7 Technologies stock overvalued right now?
Based on GuruFocus' analysis, Mach7 Technologies (ASX:M7T) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.84, compared to a current price of A$0.31 — trading 63.1% below its estimated fair value. The current 3-Year ROIIC % is 68.98 and 1893.6% above the Healthcare Providers & Services industry median of 3.46. Mach7 Technologies' overall GF Score™ is 29/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Mach7 Technologies (ASX:M7T), the current 3-Year ROIIC % is 68.98 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mach7 Technologies (ASX:M7T) Overvalued in 2026?
Based on GuruFocus' analysis, Mach7 Technologies stock appears to be undervalued.
The current stock price of A$0.31 is trading 63.1% below its estimated GF Value™ of A$0.84.
GuruFocus considers Mach7 Technologies to be Possible Value Trap.
Key valuation signals for ASX:M7T:
3-Year ROIIC %: 68.98
GF Value™: A$0.84 vs. price of A$0.31 (63.1% below fair value)
Industry Position: 1893.6% above the Healthcare Providers & Services median (#82 of 621)
No single metric tells the full story. See the ASX:M7T stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mach7 Technologies Ltd is a healthcare software company focused on enterprise imaging infrastructure. The company's vendor neutral platform enables health systems to manage, access, and exchange medical imaging data across departments, sites, and vendors. It serves across North America, Asia-Pacific, and the Middle East, with deployments ranging from academic medical centres to multi-site health networks. A substantial part of revenue is derived in the form of Subscription revenue. Geographically, it derives a majority of its revenue from North America.
29GF Score
Get the complete analysis for ASX:M7T
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:M7T has been successfully added to your 
